



October 29, 2026

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051, Maharashtra.

Symbol: STAR

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001, Maharashtra.

Scrip Code: 532531

Dear Madam/ Sir,

Sub: Press Release

Please find enclosed herewith Press Release issued by the Company titled:

**“Strides Delivers Strong Performance with Q2FY27 Revenue at ₹14,297m, Grew 17% YoY
Ex-US Markets Up 31% YoY; EBITDA Up 8% YoY to ₹2,509m, Crossing ₹2,500m
in a Quarter for the First Time”**

Board Meeting for considering the unaudited financial results for the quarter and half year ended September 30, 2026 commenced at 16:45 hrs (IST) and concluded at 18:15 hrs (IST).

The above information shall be made available on the website of the Company at www.strides.com.

This is for your information and records.

Thanks & Regards,
For **Strides Pharma Science Limited**,

MANJULA
RAMAMURTHY

Digitally signed by
MANJULA RAMAMURTHY
Date: 2026.10.29 18:33:45
+05'30'

Manjula Ramamurthy
Company Secretary & Compliance Officer
ICSI Membership No.: A30515

Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com

Strides Delivers Strong Performance with Q2FY27

Revenue at ₹14,297m, Grew 17% YoY

Ex-US Markets Up 31% YoY; EBITDA Up 8% YoY to ₹2,509m, Crossing ₹2,500m in a Quarter for the First Time

Q2FY27 Performance Highlights

- **Revenue up 17.1% YoY to ₹14,297m**, led by strong 31% YoY growth in the Ex-US Markets
- **US business at ₹6,855m (\$73m)**, up 9% YoY; 3 products launched during the quarter
- **Ex-US Markets revenue at ₹6,963m (\$74m)**, up 31% YoY, surpassing the US business in quarterly revenue for the first time
- **EBITDA up 8.4% YoY to ₹2,509m**, crossing the ₹2,500m mark in a quarter for the first time despite higher input material and freight costs; EBITDA margin at 17.6%
- **Operational PAT up 11.5% YoY to ₹1,358m**; Operational EPS at ₹14.7
- **Reported PAT up 2.0% YoY to ₹1,341m**; Reported EPS at ₹14.2

Bangalore, India, 29 October 2026 - Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q2FY27) and half year (H1FY27) ended 30 September, 2026.

Financial Highlights (In ₹m)

Particulars (₹m)	Q2FY27	Q2FY26	YoY	Q1FY27	QoQ	H1FY27	H1FY26	YoY
Revenue	14,297	12,208	17.1%	12,654	13.0%	26,951	23,406	15.1%
Gross Margin	8,003	7,056	13.4%	7,702	3.9%	15,705	13,810	13.7%
Gross Margin %	56.0%	57.8%	-180 bps	60.9%	-490 bps	58.3%	59.0%	-70 bps
EBITDA	2,509	2,316	8.4%	2,298	9.2%	4,807	4,496	6.9%
EBITDA %	17.6%	19.0%	-140 bps	18.2%	-60 bps	17.8%	19.2%	-140 bps
Operational PAT	1,358	1,218*	11.5%	1,231	10.3%	2,589	2,358*	9.8%
Operational EPS (₹)	14.7	13.2	11.6%	13.4	10.3%	28.1	25.6	9.9%
Reported PAT	1,341	1,315	2.0%	1,655	-19.0%	2,996	2,371	26.4%
Reported EPS (₹)	14.2	13.8	2.6%	17.0	-16.6%	31.2	24.6	26.7%

*Q2FY26 and H1FY26 Operational PAT and Operational EPS exclude one-time finance income of ₹185m; Operational PAT = Reported PAT excluding exceptional items

Badree Komandur, MD & Group CEO, commented on the performance and said, “Strides delivered a strong second quarter, with revenue of ₹14,297m growing ~17% YoY, driven by Ex-US Markets. Our diversification strategy continues to play out, with Ex-US Markets growing 31% YoY to ₹6,963m and, for the first time, surpassing our US business in quarterly revenue. Our US business delivered 9% YoY growth. EBITDA grew to ₹2,509m, crossing the ₹2,500m mark in a quarter for the first time. This was despite higher raw material, freight and operating costs arising from geopolitical disruptions. We remain focused on mitigating these pressures through continuous cost optimization initiatives during the year. Net Debt increased by ₹2,114m during H1 due to an elongated cash-to-cash cycle and higher inventory holding to navigate current market conditions. We expect the Net Debt to EBITDA ratio to stabilize by the end of the year. We are also pleased to welcome Mr. Biren Gabhawala to our Board as an Independent Director. His deep expertise in financial reporting, audit and corporate governance will further strengthen the Board’s oversight. While the external environment remains dynamic, we are committed to

delivering sustainable and profitable growth.”

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com.

For further information, please contact:

Investor Relations Vikesh Kumar: Group CFO investor-relations@strides.com Saurabh Ambaselkar: +91 99609 31220 saurabh.ambaselkar@strides.com Strides Pharma Science Limited Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076	Corporate Communication Pallavi Panchmatia: +91 80 6784 0193 Pallavi.panchmatia@strides.com Abhilash Mukherjee: +91 89044 28907 Abhilash.Mukherjee@strides.com Adrita Chatterjee: +91 92842 40813 adrita.chatterjee@adfactorspr.com
---	---

October 29, 2026

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051, Maharashtra.

Symbol: STAR

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001, Maharashtra.

Scrip Code: 532531

Dear Madam/ Sir,

Sub: Earnings Presentation for the quarter and half year ended September 30, 2026

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
("SEBI Listing Regulations")**

We are pleased to enclose the Earnings Presentation for the quarter and half year ended September 30, 2026.

The Board Meeting for considering the unaudited financial results for the quarter and half year ended September 30, 2026 commenced at 16:45 hrs IST and concluded at 18:15 hrs IST.

The above information shall be made available on the website of the Company at www.strides.com.

This is for your information and records.

Thanks & Regards,

For **Strides Pharma Science Limited**,

**MANJULA
RAMAMURTHY**

Digitally signed by MANJULA
RAMAMURTHY
Date: 2026.10.29 18:35:09 +05'30'

Manjula Ramamurthy
Company Secretary & Compliance Officer
ICSI Membership No.: A30515

Encl. as above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199
corpcomm@strides.com; www.strides.com



Q2 & H1FY27

Earnings Presentation

October 29, 2026

Strides Pharma Science Limited

Health where it matters



Safe Harbor



Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Strides Delivers a Strong Performance with Revenue at ₹14,297m, Grew ~17% YoY; Ex-US Markets Grew 31% YoY



EBITDA Grew 8% YoY to ₹2,509m, Despite increase in input material and freight cost due to geopolitical disruptions. Operational PAT at ₹1,358m with Operational EPS at ₹14.7; Reported PAT at ₹1,341m

Performance Highlights	Q2FY27	Q2FY26	YoY change
Revenue (₹m)	14,297	12,208	▲ 17.1%
Gross margin (₹m)	8,003	7,056	▲ 13.4%
Gross margin (%)	56.0%	57.8%	
EBITDA (₹m)	2,509	2,316	▲ 8.4%
EBITDA margin (%)	17.6%	19.0%	
Operational PAT (₹m)	1,358	1,218*	▲ 11.5%
Operational EPS (₹)	14.7	13.2*	
Reported PAT (₹m)	1,341	1,315	▲ 2.0%

“ Badree Komandur MD and Group CEO

Strides delivered a strong second quarter, with revenue of ₹14,297m growing ~17% YoY, driven by Ex-US Markets. Our diversification strategy continues to play out, with Ex-US Markets growing 31% YoY to ₹6,963m and, for the first time, surpassing our US business in quarterly revenue. Our US business delivered 9% YoY growth.

EBITDA grew to ₹2,509m, crossing the ₹2,500m mark in a quarter for the first time. This was despite higher raw material, freight and operating costs arising from geopolitical disruptions. We remain focused on mitigating these pressures through continuous cost optimization initiatives during the year.

Net Debt increased by ₹2,114m during H1 due to an elongated cash-to-cash cycle and higher inventory holding to navigate current market conditions. We expect the Net Debt to EBITDA ratio to stabilize by the end of the year.

We are also pleased to welcome Mr. Biren Gabhawala to our Board as an Independent Director. His deep expertise in financial reporting, audit and corporate governance will further strengthen the Board's oversight.

While the external environment remains dynamic, we are committed to delivering sustainable and profitable growth.

* Excluding one-time finance income of ₹185m in Q2FY26; on a reported basis, Operational EPS is down 3.2% YoY
Operational PAT = Reported PAT excluding exceptional items

H1FY27 Performance: Revenue at ₹26,951m, Grew 15% YoY

EBITDA Grew 7% YoY to ₹4,807m; Operational PAT at ₹2,589m with Operational EPS at ₹28.1; Reported PAT at ₹2,996m



Performance Highlights	H1FY27	H1FY26	YoY change
Revenue (₹m)	26,951	23,406	▲ 15.1%
Gross margin (₹m)	15,705	13,810	▲ 13.7%
Gross margin (%)	58.3%	59.0%	
EBITDA (₹m)	4,807	4,496	▲ 6.9%
EBITDA margin (%)	17.8%	19.2%	
Operational PAT (₹m)	2,589	2,358*	▲ 9.8%
Operational EPS (₹)	28.1	25.6*	
Reported PAT (₹m)	2,996	2,371	▲ 26.4%

H1FY27 Performance

📈 **Revenue grew** 15% YoY to ₹26,951m driven by Ex-US Markets

📈 **Ex-US Markets** grew 24% YoY to ₹12,838m

% **Margins** were impacted due to higher material and logistics costs

📊 **EBITDA** grew 7% YoY to ₹4,807m

🕒 **Operational PAT** grew 9.8% YoY to ₹2,589m; Operational EPS at ₹28.1


*H1FY26 Operational PAT and EPS exclude one-time finance income of ₹185m; on a reported basis, Operational PAT is up 1.8% and Operational EPS up 1.8% YoY. Operational PAT = Reported PAT excluding exceptional items

Predictable Growth Across Key Metrics Over the Last 10 Quarters

Steady Compounding in Last 10 Quarters




Total Revenue (₹m)




+36% Q2FY27 vs Q1FY25
~14% CAGR annualised, 9 quarters

EBITDA (₹m)



+32% Q2FY27 vs Q1FY25
~13% CAGR annualised, 9 quarters

Operational PAT (₹m)




2.2x Q2FY27 vs Q1FY25
~41% CAGR annualised, 9 quarters

*Q2FY26 Operational PAT excludes one-time finance income of ₹185m; Operational PAT = Reported PAT excluding exceptional items

Ex-US Growth Accelerates Diversification: Surpasses US Revenue for the First Time in Q2FY27

Revenue Mix – H1 (%)



US (₹m)

+7% YoY



Ex-US (₹m)

+24% YoY




Access* (₹m)

+30% YoY




Revenue Mix – Q2 (%)




US (₹m)

+9% YoY



Ex-US (₹m)

+31% YoY



Access* (₹m)

-21% YoY



*Tactical Business



FY28 - \$375m US Revenue Aspiration

Update

Health where it matters

Growth Ambition Intact: US Revenue Aspiration of ~\$375m shifts beyond FY28; Ex-US acceleration and disciplined US Investment underpin the next phase of profitable growth

US Market | Timing changes

7%

YoY revenue growth in H1FY27

- Normalised market opportunities**
Drug-shortage opportunities in oral solids have largely dissipated
- Higher operating costs**
Higher material costs and inventory to sustain industry-leading service levels
- Controlled Substance quotas**
Quota allocations constrain growth; expected to improve progressively

Strategic Response


- Profitability-led growth**
Protect established profitability thresholds; drive margin-accretive revenues. Maintain selective launches, and expand differentiated platforms
- Rebalancing growth engines**
Focusing on the Ex-US business to drive geographical diversification and accelerate overall revenue growth
- US remains strategic growth market**
Growth anchored in differentiated platforms (nasal sprays, patches, films) and a progressively expanding Controlled Substances portfolio

Ex-US Markets | Accelerating

24%

YoY revenue growth in H1FY27

Ex-US revenue as % of US (goal: 100% by FY28)



- Surpassed US for the first time**
Q2FY27 Ex-US ₹6,963m vs US ₹6,855m
- Margin expansion**
Scale, operating leverage, portfolio mix

For US, the timing changes, ambition is intact. Growth quality and returns remain a key priority
Ex-US acceleration and margin expansion to sustain our long-term ambitions

YoY growth on ₹ reported numbers; Ex-US % of US = Ex-US Markets revenue + US revenue




US Market

Health where it matters

Q2FY27 Revenue at ₹6,855m (\$73m), Grew 9% YoY, H2 Expected to be Stronger with New Launches


H1FY27 Performance (₹/\$m)



Comments

- Q2FY27 revenue at \$73m, 9% YoY growth
- Launched 3 products in Q2FY27
- Continue to rank amongst the top 3 in 38 products, enjoying a market-leading position, contributing ~70% of our total US revenue
- Industry-leading service levels across all our customers
- 230 ANDAs filed, 212 ANDAs approved (154 products) as of Oct'26

Quarterly trend (₹/\$m)



Our Approach | US remains a strategic growth market

A disciplined US portfolio shifting toward higher-value, differentiated products, with a larger Controlled Substances opportunity ahead.

Proven Discipline

- 154 approved products, 75 products commercialised, 38 products in market-leading positions
- 40+ value-accretive products in active pipeline, filings and approvals in a phased manner
- Commercialisation of all products through FY30
- GDUFA goal date for 1 Nasal Spray in H2FY27

Controlled Substances (CS)

- 5 commercialised CS products contribute ~6% of US revenue (TAM* \$750m)
- 10+ CS products in the pipeline, including nasal sprays, patches and films, to expand the portfolio significantly (TAM* \$4.5bn)
- Current CS portfolio is constrained by quota allocations; niche pipeline products require limited API quota and are expected to drive the ramp-up
- Relaunch of 1 CS patch in H2FY27, full-year benefit to flow in FY28
- Chestnut Ridge, our US facility, has the capacity and expertise to bolster this portfolio strategy, as regulations require these products to be manufactured in the US

YoY growth on ₹ reported numbers

*Total Addressable Market as per IQVIA as of Aug'26




Ex-US Markets

Health where it matters

Ex-US Markets Revenue at ₹6,963m (\$74m), Grew 31% YoY, Driven by Strong Performance Across Markets




H1FY27 Performance (₹/\$m)



Comments

- All markets except US and institutional business form part of the Ex-US Markets
- QoQ growth led by expansion in the UK, Nordics and South Africa
- Strong performance in the Europe partnered business, supported by higher offtake of key products
- Africa operations led by the Brands business delivered stellar growth
- Sustained momentum in new filings and launches across markets

Quarterly trend (₹/\$m)



Our Approach

- Leverage our well-established commercial infrastructure outside the US to gain market share and accelerate launches
- A strong launch pipeline, an expanding customer base and conversion of a healthy opportunity funnel to drive growth
- Portfolio maximization, focused R&D investment and channel partner expansion to broaden our offering across markets
- Significant regulatory filings underway for the new territories

YoY growth on ₹ reported numbers



Financial Performance

Strong Financial Discipline Enabled Profitable Growth

Health where it matters

Income Statement – Q2FY27 Operational PAT at ₹1,358m; EPS at ₹14.7



Particulars (₹m)	Q2FY27	Q2FY26	YoY	Q1FY27	QoQ	H1FY27	H1FY26	YoY
I. Revenue	14,297	12,208	17.1%	12,654	13.0%	26,951	23,406	15.1%
II. Material Costs	6,294	5,153		4,952		11,246	9,595	
III. Gross Margin (I- II)	8,003	7,056	13.4%	7,702	3.9%	15,705	13,810	13.7%
Gross Margin %	56.0%	57.8%	-180 bps	60.9%	-490 bps	58.3%	59.0%	-70 bps
a. Personnel Cost	2,383	2,268		2,430		4,813	4,523	
b. Other Opex	3,111	2,472		2,975		6,086	4,791	
IV. Total Opex (a+b)	5,494	4,740		5,404		10,898	9,314	
V. EBITDA (III-IV)	2,509	2,316	8.4%	2,298	9.2%	4,807	4,496	6.9%
EBITDA Margin %	17.6%	19.0%	-140 bps	18.2%	-60 bps	17.8%	19.2%	-140 bps
c. Depreciation and amortisation	572	496		564		1,136	985	
d. Net Finance Cost	430	204*		361		791	611*	
e. Other Income	(5)	(14)		(5)		(10)	(32)	
f. Exceptional items – net (gain)/loss	17	88		(632)		(615)	171	
g. JV share of loss	(9)	10		13		4	9	
VI. Profit/ (loss) before tax (V-c-d-e-f-g)	1,504	1,531	-1.7%	1,996	-24.6%	3,501	2,752	27.2%
h. Tax	163	216		341		504	380	
VII. Profit/(loss) after tax for the period	1,341	1,315	2.0%	1,655	-19.0%	2,996	2,371	26.4%
VIII. Reported EPS (₹)	14.2	13.8	2.6%	17.0	-16.6%	31.2	24.6	26.7%

*Q2FY26 includes one-time finance income of ₹185m
Operational PAT = Reported PAT excluding exceptional items

Reported Net Debt at ₹16,479m with a Net Debt/EBITDA of 1.72x

Net Debt Rose by ₹2,114m in H1 to Fund Growth and Higher Working Capital Amid Geopolitical Disruptions; Remains at Comfortable Levels and Expected to Moderate in Coming Quarters



Particulars (₹m)	Mar'26	Sept'26
Working capital loans	10,393	12,054
Long term loans	6,294	6,417
Gross debt	16,687	18,471
Cash and cash equivalents	(2,322)	(1,992)
Reported net debt[#]	14,365	16,479

Q2 & H1FY27 update

- Net debt increased by ₹2,114m during H1FY27 due to an elongated C2C cycle with higher inventory holding to manage the current macro environment.
- Net Debt to EBITDA ratio to stabilize by end of the year
- H1FY27 operating cashflow at ₹1,024m
- Strides' retained interest in OneSource is currently worth ₹2,900m (28 Oct'26) (not adjusted from net debt)

Finance cost (₹m)	Q1FY27	Q2FY27
Interest cost on borrowings (A)	325	391
Other finance charges (B)	81	74
Finance income (C)	44	36
Net finance cost (A+B-C)	361	430

Priorities


- Focus on operating cashflow generation
- While the challenging external environment has elongated cash-to-cash cycle, we remain focused on improving the Net Debt/EBITDA ratio
- Committed to drive long-term growth through impactful R&D and Capex programs

[#]Investment held in OneSource is not considered for Net debt computation


Key Metrics Remain Resilient Despite External Headwinds




Net Debt to Equity (x)




Net Debt to EBITDA (x)




Cash to Cash Cycle (Days)




Current Ratio (x)



RoCE (%)



Fixed Asset Turnover Ratio (x)



All ratios are on TTM basis; For RoCE, Capital Employed = Equity + Net Debt

Balance Sheet

Strong Corporate Governance and Corporate Actions Improved the Balance Sheet Position



Particulars (₹m)	31-Mar-24	31-Mar-25	31-Mar-26	30-Sep-26
Assets				
Net Tangible Assets (including CWIP)	8,809	9,220	10,756	11,369
Right-of-use assets	895	695	782	479
Goodwill and Other Intangibles	10,565	11,145	13,941	14,475
Investments	1,969	3,397	2,914	3,461
Other Non-current Assets	2,659	2,111	1,438	1,701
Tax assets	3,809	2,929	3,309	2,916
Inventories	11,262	12,776	16,348	18,776
Cash and bank balances (including Current investments)	2,969	2,063	2,131	1,475
Trade receivables	11,419	12,029	12,890	14,640
Other current assets	4,040	4,121	4,764	5,485
Total Assets	58,398	60,487	69,272	74,775
Liabilities				
Equity	21,256	25,518	31,076	34,165
Non-controlling interest	(539)	346	418	540
Equity	20,717	25,865	31,493	34,705
Borrowings	24,145	17,956	16,687	18,471
Lease liabilities	1,023	840	893	577
Tax liabilities	808	1,534	1,691	1,669
Other non-current liabilities	137	147	312	364
Provisions	1,632	1,951	2,227	2,105
Trade payables	8,516	10,325	13,097	14,288
Other current liabilities	1,420	1,868	2,872	2,596
Total Equity and Liabilities	58,398	60,487	69,272	74,775

FY24 numbers include Softgel business



Corporate Governance

Health where it matters

Strengthening Board Governance: Mr. Biren Gabhawala Joins the Board as Independent Director



With his appointment*, Independent Directors will make up 6 of the 10 Board members



Mr. Biren Gabhawala

Non-Executive Independent Director

Mr. Biren Gabhawala, Chartered Accountant (FCA)

Biren, aged 60 years, is a Chartered Accountant with more than three decades of experience in accounting, audit, taxation, financial reporting, corporate finance, M&A, FEMA, business consulting, valuations and insolvency-related matters.

He currently serves as a Senior Partner at C.M. Gabhawala & Co., a Mumbai-based chartered accountancy firm. He has advised organisations across diverse industries and stages of business development on financial reporting, taxation, audit, cross-border transactions, deal structuring, corporate finance, valuations and regulatory matters.

Biren also has extensive experience on the boards and committees of listed companies. He served as an Independent Director of eClerx Services (2011–2025) and 3M India (2014–2024) including as Chairperson of their respective Audit Committees. He also served on the Stakeholders' Grievance/Relationship, Corporate Social Responsibility and Nomination and Remuneration Committees, as applicable.

His extensive experience is expected to strengthen the Board's financial oversight, internal controls, risk management and corporate governance capabilities.

*w.e.f. November 1, 2026, subject to shareholder approval

Q2 & H1FY27 Earnings Call Details



Strides invites you to interact with the senior management on Q2 & H1FY27 performance

October 30, 2026

10:00 am IST / 4:30 am GMT / 12:30 am EDT / 12:30 pm HKT

[Pre-register and join without the operator](#)

Participants from the management

Badree Komandur

Managing Director & Group CEO

Vikesh Kumar

Group CFO

Join through an operator using dial-in numbers

Location	Dial-in number
India primary	+91 22 6280 1434 / +91 22 7115 8838
USA	18667462133
UK	08081011573
Singapore	8001012045
Hong Kong	800964448

For any query, please reach out to:

Investor Relations: saurabh.ambaselkar@strides.com



Health where it matters

Thank You

To know more:



www.strides.com



investor-relations@strides.com

Stay Connected



© 2026 Strides Pharma
All Rights Reserved.

This presentation is intended solely for the use of the individual or entity to whom it is addressed. If you are not the intended recipient, please notify the sender immediately and delete the presentation from your system. Any unauthorized use, disclosure, copying, or distribution of this presentation is strictly prohibited. The information contained in this presentation is for informational purposes only and is provided "as is" without any warranties, express or implied. Strides makes no representations as to the accuracy or completeness of the information in this presentation or any consequences resulting from the use of such information.

This presentation may contain confidential and privileged information. Unauthorized disclosure or use of such information is strictly prohibited. Strides reserves the right to make changes to this presentation at any time without notice. The views and opinions expressed in this presentation are those of the author(s) and do not necessarily reflect the official policy or position of Strides. Strides accepts no liability for any damage caused by any virus transmitted by this presentation. It is the responsibility of the recipient to ensure that the presentation is virus-free before opening. By viewing or using this presentation, you agree to be bound by the terms and conditions of this disclaimer.